molecules of the month

GBT/Pfizer HbS polymerization inhibitor

FIC, oral, QD, reversible covalent HbS pol. inhibitor

accelerated FDA approval for hemolytic anemia in SCD

opt. + SBDD of natural product (5HMF) analogs

voxelotor (GBT440, OXBRYTA)

Global Blood Therapeutics, SSF, CA / Pfizer, NY

2 mins read

Voxelotor is a first-in-class, reversible covalent aldehyde drug that prevents the hemoglobin polymerization, a primary driver of sickle cell disease. Approved in 2019, this molecule represented a scientific milestone as a modern example of a reversible covalent drug being approved in a chronic indication. It is the first oral drug that improves hemoglobin levels and prevents hemolysis in sickle cell disease – in the pivotal Ph. III HOPE trial of 274 patients, more patients (51%) in the 1500-mg voxelotor group had a hemoglobin response (an increase of more than 1.0 g/dL) at 24 weeks than those in the placebo group (7%). A follow-up analysis at 72 weeks showed that improvements in hemoglobin concentrations were sustained. The molecule is of significant…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: